MX385188B - Vacuna de rinitis equina. - Google Patents

Vacuna de rinitis equina.

Info

Publication number
MX385188B
MX385188B MX2017004273A MX2017004273A MX385188B MX 385188 B MX385188 B MX 385188B MX 2017004273 A MX2017004273 A MX 2017004273A MX 2017004273 A MX2017004273 A MX 2017004273A MX 385188 B MX385188 B MX 385188B
Authority
MX
Mexico
Prior art keywords
equine rhinitis
equine
rhinitis vaccine
vaccine
virus
Prior art date
Application number
MX2017004273A
Other languages
English (en)
Inventor
Andres Diaz-Mendez
Kristina J Hennessy
Laurent Viel
Phillip Wayne Hayes
Original Assignee
Boehringer Ingelheim Vetmedica Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Vetmedica Inc filed Critical Boehringer Ingelheim Vetmedica Inc
Publication of MX385188B publication Critical patent/MX385188B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32711—Rhinovirus
    • C12N2770/32734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Otolaryngology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invención se refiere a composiciones inmunógenas contra virus de rinitis equina, en particular virus de rinitis equina A y B y métodos para su uso y su preparación. Las composiciones inmunógenas, en modalidades alternativas, también incluyen otros agentes patógenos de equinos.
MX2017004273A 2011-03-14 2012-03-12 Vacuna de rinitis equina. MX385188B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161452390P 2011-03-14 2011-03-14
US201161510226P 2011-07-21 2011-07-21
PCT/US2012/028706 WO2012125525A2 (en) 2011-03-14 2012-03-12 Equine rhinitis vaccine

Publications (1)

Publication Number Publication Date
MX385188B true MX385188B (es) 2025-03-14

Family

ID=45876924

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2017004273A MX385188B (es) 2011-03-14 2012-03-12 Vacuna de rinitis equina.
MX2013010125A MX350718B (es) 2011-03-14 2012-03-12 Vacuna de rinitis equina.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2013010125A MX350718B (es) 2011-03-14 2012-03-12 Vacuna de rinitis equina.

Country Status (12)

Country Link
US (1) US9187730B2 (es)
EP (2) EP2772266B1 (es)
AR (1) AR085800A1 (es)
AU (2) AU2012229192B2 (es)
BR (2) BR112013023354B1 (es)
CA (2) CA2829226C (es)
ES (2) ES2748555T3 (es)
MA (1) MA35303B1 (es)
MX (2) MX385188B (es)
NZ (1) NZ614147A (es)
TW (1) TW201300537A (es)
WO (1) WO2012125525A2 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2829226C (en) 2011-03-14 2023-01-03 Boehringer Ingelheim Vetmedica, Inc. Equine rhinitis vaccine
CA2967532A1 (en) 2014-11-24 2016-06-02 Intervet International B.V. Inactivated equine influenza virus vaccines
US10064930B2 (en) * 2015-01-16 2018-09-04 Boehringer-Ingelheim Vermedica, Inc. Immunogenic compositions and methods for pigeon fever
EP3720488A1 (en) * 2017-12-04 2020-10-14 Intervet International B.V. Vaccination with replicon particles and oil adjuvant

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2702373B1 (fr) 1993-03-08 1996-06-07 Rhone Merieux Emulsions vaccinales fluides eau-dans-l'huile contenant une huile métabolisable.
AUPN720195A0 (en) * 1995-12-18 1996-01-18 University Of Melbourne, The Equine rhinovirus 1 proteins
US7227011B2 (en) 1998-06-04 2007-06-05 United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Nucleic acid vaccines for prevention of flavivirus infection
US6177082B1 (en) 1998-08-13 2001-01-23 The University Of Pittsburgh-Of The Commonwealth System Of Higher Education Cold-adapted equine influenza viruses
US7425437B2 (en) 1999-11-26 2008-09-16 Crucell Holland B.V. Vaccines against West Nile Virus
JP5230052B2 (ja) 2000-05-26 2013-07-10 イデニクス（ケイマン）リミテツド フラビウイルスおよびペスチウイルス治療のための方法および組成物
WO2002067899A1 (en) 2001-02-28 2002-09-06 Akzo Nobel N.V. Injectable water-in-oil emulsions
US20030148261A1 (en) 2001-03-12 2003-08-07 Erol Fikrig Compositions and methods comprising West Nile virus polypeptides
US20030104008A1 (en) 2001-04-06 2003-06-05 Loosmore Sheena May Recombinant vaccine against west nile virus
AUPR472501A0 (en) * 2001-05-02 2001-05-24 Council Of The Queensland Institute Of Medical Research, The Equine rhinitis a virus antigens
EP2283858A3 (en) 2001-07-27 2011-03-23 Wyeth LLC West Nile Vaccine
US6878372B2 (en) 2001-10-19 2005-04-12 Acambis Inc. Methods of preventing and treating flavivirus infection in animals
WO2004045529A2 (en) 2002-11-15 2004-06-03 Acambis, Inc. West nile virus vaccine
CA2432738A1 (en) 2003-02-26 2004-08-26 Philippe Despres New dengue and west nile viruses proteins and genes coding the foregoing, and their use in vaccinal, therapeutic and diagnostic applications
WO2005024427A2 (en) 2003-09-09 2005-03-17 Idexx Laboratories, Inc. Detection of west nile virus infection and vaccination
US7459163B2 (en) 2004-02-25 2008-12-02 University Of Kansas Infectious DNA as a vaccine against west nile and other flaviviruses
US7862829B2 (en) 2004-07-09 2011-01-04 University Of North Carolina At Chapel Hill Viral adjuvants
US7482017B2 (en) 2004-09-09 2009-01-27 Research Development Foundation Flavivirus variants having phenotypic variation and immunogenic compositions thereof
EP1645283A1 (en) 2004-10-08 2006-04-12 Chiron Behring GmbH & Co. KG Combination vaccine
CA2591665C (en) 2004-12-20 2015-05-05 Crucell Holland B.V. Binding molecules capable of neutralizing west nile virus and uses thereof
US7959929B2 (en) 2005-04-21 2011-06-14 University Of Florida Research Foundation, Inc. Materials and methods for respiratory disease control in canines
CA2612047C (en) 2005-06-24 2015-05-12 Intervet International B.V. Inactivated chimeric vaccines and related methods of use
US7384642B2 (en) 2005-08-25 2008-06-10 Merial Limited Canine influenza vaccines
US7425336B2 (en) 2005-08-25 2008-09-16 Mevial Limited Canine influenza vaccines
EP1945254A1 (en) 2005-10-07 2008-07-23 Pfizer Products Incorporated Vaccines and methods to treat canine influenza
US7468187B2 (en) 2005-10-18 2008-12-23 Iowa State University Research Foundation, Inc. Canine influenza virus and related compositions and methods of use
WO2007051763A1 (en) 2005-11-01 2007-05-10 Intervet International B.V. Prime boost vaccine for the protection of equines against equine influenza
US7455842B2 (en) 2005-12-05 2008-11-25 University Of Kansas Chimeric West Nile viruses and uses thereof
KR100850545B1 (ko) 2007-10-30 2008-08-05 주식회사 에니멀제네틱스 신규한 개 인플루엔자 바이러스 및 이의 백신
MX2011002071A (es) 2008-08-29 2011-04-05 Boehringer Ingelheim Vetmed Vacuna para el virus del nilo occidental.
CA2829226C (en) 2011-03-14 2023-01-03 Boehringer Ingelheim Vetmedica, Inc. Equine rhinitis vaccine

Also Published As

Publication number Publication date
BR112013023354A2 (pt) 2016-12-06
MX2013010125A (es) 2013-10-07
CA2829226C (en) 2023-01-03
US20120237543A1 (en) 2012-09-20
AU2017201526B2 (en) 2019-07-18
EP2686012A2 (en) 2014-01-22
WO2012125525A2 (en) 2012-09-20
NZ708320A (en) 2016-08-26
CA2829226A1 (en) 2012-09-20
CA3018230A1 (en) 2012-09-20
MA35303B1 (fr) 2014-08-01
AU2017201526A1 (en) 2017-03-30
BR122019023542B1 (pt) 2022-02-15
MX350718B (es) 2017-09-14
AR085800A1 (es) 2013-10-30
EP2772266B1 (en) 2019-07-31
ES2842595T3 (es) 2021-07-14
EP2686012B1 (en) 2020-12-02
BR112013023354B1 (pt) 2022-02-15
AU2012229192B2 (en) 2017-04-20
AU2012229192A1 (en) 2013-08-29
TW201300537A (zh) 2013-01-01
EP2772266A1 (en) 2014-09-03
WO2012125525A3 (en) 2013-02-28
ES2748555T3 (es) 2020-03-17
AU2017201526C1 (en) 2019-10-24
NZ614147A (en) 2015-08-28
US9187730B2 (en) 2015-11-17

Similar Documents

Publication Publication Date Title
MX2012009581A (es) Vacunas para su uso en la profilaxis y tratamiento de la enfermedad del virus de influenza.
EA201291157A1 (ru) Мультивалентные вакцины с синтетическими наноносителями
MX2020011717A (es) Composiciones de vacuna que tienen estabilidad e inmunogenicidad mejoradas.
MX2021006342A (es) Mutantes de virus de influenza y usos para los mismos.
WO2016019134A8 (en) Flagellin-based agents and uses including effective vaccination
IL244597B (en) Replication suppressors of influenza viruses, preparations containing them and their uses
TR201813877T4 (tr) Spi̇nal müsküler atrofi̇ni̇n tedavi̇ edi̇lmesi̇ne yöneli̇k bi̇leşi̇kler.
JP2014501485A5 (es)
MX388720B (es) Composiciones a base de nanoparticulas.
BR112015003259A2 (pt) composto, composição farmacêutica, e, composição de vacina.
TW201144301A (en) Processes for preparing linezolid
PH12013502442A1 (en) Inactivated dengue virus vaccine
DK3564378T5 (da) Immunogen sammensætning
JP2013536184A5 (es)
MY189495A (en) Hand, foot, and mouth vaccines and methods of manufacture and use thereof
LT2683245T (lt) Būdai ir kompozicijos, skirti depresijai gydyti panaudojant ciklobenzapriną
MX347911B (es) Vacuna contra virus de diarrea viral de bovinos.
MX385188B (es) Vacuna de rinitis equina.
EP2694102A4 (en) PROCESS FOR IMPROVED VACCINE IMMUNOGENICITY
PL3076996T3 (pl) Szczepionka przeciwko cirkowirusowi świń typu 2
WO2014167582A3 (en) Vaccine composition for prophylaxis in ruminants
DK2938356T3 (da) Immunogen sammensætning som omfatter mycoplasma-antigener
PL2569007T3 (pl) Szczepionka przeciwko Mycoplasma Hyopneumoniae, odpowiednia do podawania w obecności przeciwciał pochodzących od matki
EA201690378A1 (ru) Вакцинные композиции против наркотической зависимости
EA201300380A1 (ru) Рекомбинантная mycobacterium в качестве вакцины для применения у людей